Axora Medical, Inc. appears in FDA device records as the applicant for P140013, approved on 27 July 2015 for the Minerva Endometrial Ablation System. The approval order describes the device as intended for ablation of the endometrial lining of the uterus in pre-menopausal women with menorrhagia due to benign causes for whom childbearing is complete. The filing lists Jacksonville, Florida as the applicant address, and the advisory committee is recorded as Obstetrics/Gynecology. [2][10]

The approved device and its classification

P140013 covers the Minerva Endometrial Ablation System under product code MNB, generic name "Device, thermal ablation, endometrial," with device class 3 and the Obstetrics/Gynecology advisory committee. The approval order carries docket number 15M-2739 and a Federal Register notice date of 27 August 2015. Axora Medical's own safety page lists the Minerva EAS Endometrial Ablation System among the products for which it publishes prescriptive information. [2][10]

Axora Medical's product page describes the Minerva EAS as engineered to deliver coverage by targeting the least ablated tissue in real time, and states that the system is now part of the Axora Medical portfolio. Those are company-published characterizations; the linked FDA records do not evaluate them. [4]

Supplement S019 and its scope

Supplement S019 was received on 14 October 2026 and decided on 5 November 2026 under decision code OK30, a 30-Day Notice. The supplement type is recorded as a 30-Day Notice with reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The applicant order statement describes elimination of duplicate final QC functional testing and 30-cycle burn-in performed by the PMA holder on Minerva RF Controllers following completion of equivalent testing at Apical Instruments. [1]

The supplement was not flagged for expedited review, and the advisory committee remained Obstetrics/Gynecology. The record identifies the Minerva RF Controller as the component affected by the manufacturing change, tying the supplement to a specific hardware element of the approved system. [1]

Filing history in the linked FDA records

The supplied collection links two PMA records for this applicant, both under P140013: the original approval and supplement S019. The collection's decision counts are one APPR and one OK30, matching the two-record sample. A separate openFDA query response reports a total of 19 results for P140013, indicating additional supplements exist beyond the two linked records; those supplements are not described here. [1][2][9]

One anchor from that query response references controller software intended to reduce the occurrence of false error codes, associated with supplement S004. The linked FDA records do not give a decision date or decision code for S004, so its outcome is unknown. [9]

Identity and published materials

The applicant name on both linked PMA records is Axora Medical, Inc., with a filing address of 1 Independent Dr. Suite 2300, Jacksonville, FL. Axora Medical's safety page publishes a Sunnyvale, California address in its footer. Neither address is established here as a corporate headquarters, and the public documents do not document ownership, parent companies or brand relationships. [1][2][10]

Axora Medical's safety page also lists other product names, including Genesys HTA, Symphion, Resectr, HER izon, HER izon RD5 and Nitronox Plus, as sections of its safety information. The linked FDA records link only the Minerva Endometrial Ablation System to this applicant, so regulatory status for the other listed products is unknown. [10]